chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Gave the first dose to 6 patients between the ages of 16 - 17 years old; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Gave the first dose to 6 patients between the ages of 16 - 17 years old) in an adolescent patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Gave the first dose to 6 patients between the ages of 16 - 17 years old). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Gave the first dose to 6 patients between the ages of 16 - 17 years old) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided.  No treatment medication was provided.  The reporter was a Chief Clinical Officer (MD).  No patient details available.
24 y/o male, Senior airman calls the DOD call center with a c\o difuse skin rash some 8-9 days after receipt of primary SPV and Typhoid vaccines. Symptoms: Rash, diffuse, Pruritis, Flu-like symptoms- 96 hours.
I felt anxieties; Shortness of breath; This spontaneous case was reported by a consumer and describes the occurrence of ANXIETY (I felt anxieties) and DYSPNOEA (Shortness of breath) in a 29-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: JANSSEN COVID-19 VACCINE. Past adverse reactions to the above products included No adverse event with JANSSEN COVID-19 VACCINE. Concurrent medical conditions included Asthma.    On 22-Dec-2021 at 5:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In December 2021, the patient experienced ANXIETY (I felt anxieties) and DYSPNOEA (Shortness of breath). At the time of the report, ANXIETY (I felt anxieties) and DYSPNOEA (Shortness of breath) outcome was unknown.            Concomitant medications were not provided. Treatment information was not provided.
School nurse reported that patient had complained of arm hurting after receiving flu vaccine at school clinic. Patient told school nurse a few weeks ago that her arm still hurt and she couldn't raise her arm without pain.  Patient went to see her doctor and was given an x-ray. Dr. told patient that shot was given "too high".
I started coughing on the 16th of January. I couldn't eat or sleep. I went to the ER on the 22nd of January. They did not check for anything. They said I had a sinus infection. That Wednesday I went to my PCP due to not feeling any better. The gave me breathing treatments. I was still having weakness and tiredness. On the 21st of February I went to see a doctor. They put me on more lisinopril. At this point it is still not under control. I had a stress test last week which turned out okay. My doctor said that they think it could have been COVID.
Patient complained of dizziness, abdominal pain, nausea, and near syncope.
Pt had headache for the last week. J&J vaccine on 4/10, dxed with cerebral venous thrombosis.  Pt's age is 47, not 46. Form would not allow me to put in pt's age and cited an error with pt's DOB.
Approximately 10 days after receiving my vaccine, I started getting hives. Hives appeared in different areas of my body every few hours. Hives have continued to appear for over 5 weeks.
first dose of the Shingrix/ in August 2018.Can I still get the second dose or due I need to receive both doses again; This case was reported by a consumer via (Shingrix GSK Chatbot) interactive digital media and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose of Shingrix received in August 2018).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The case was reported by the patient for herself/himself. The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix , which led to incomplete course of vaccination. The patient asked, can he or she still get the second dose or the patient need to receive both the doses again. No further information was reported.
Pt recvd 1st dose of vax on 14MAY92 & on 15MAY92 devel fatigue & weakness; sx progressed & devel arthralgia w/pain in neck & shoulder & edema of hands, ankles & feet w/pain & stiffness; seen in ER on 18MAY92; liver function tests were nl;
persistent pain at vaccination location, nearly 1 month post vaccination. Pain is now more of a stiffness quality
Frequent vomiting for 60 hours, followed by severe diarrhea for the next 72 hours. Vomiting/diarrhea for five and a half days total.
Patient had large emesis around 0730 on 4-16-2015 after am feeding. Patient was taken to daycare and reported to the patient's mother that he was very tired and did not want any bottles for that day. Mother took infant to local ER who transferred to hospital. Patient did have a bloody stool while admitted to ER. Patient was admitted to the hospital as inpatient and later diagnosed with intussusception.
Pt received DTaP (R) arm Varicella (R) arm on 12/1 then 12/4 pt developed large bullae, required PO clindamycin, BENADRYL. That resolved but then on 12/10 developed similar red/warm region on (L) thigh (no vaccine given there) and 12/13 bullae also formed so admitted to hospital.
Information has been received from a registered nurse referring to multiple unspecified patients of unknown age and gender. The patients' concurrent condition, medical history and concomitant medication were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX (dose, and route were unknown, lot # and expiration date were L042265, 26-OCT-2017; L049535, 08-DEC-2017; M010480, 01-MAR-2018). No adverse event was reported. This is one of two reports received from the same reporter. Additional information has been requested.
Sore throat, swollen lymph nodes, fatigue, ache-y-ness, head ache, coughing, chills and sweats, eventual sneezing and draining (today 12/28).  Getting lots of rest and fluids, aspirin, Nyquil at night.
Day off sensation going up my left arm to my head Headache dizzy lightheadedness and nausea almost fainting. Bp 115/70 hr 80. Tylenol helped with headache but head still felt heavy.  1st day Chills and extreme fatigue  2nd day fatigue nausea  3rd day fatigue nausea severe headache ?exploding? after getting up from picking up toys off the grown blood pressure 90/60 .
Facial swelling & redness in right cheek to his mouth.  No itching. Next morning (today) redness area was still about the same, but now both cheeks were puffy and pt. says they feel "tight".  Swelling extends down into his beard area.  No itching.  No tongue or throat swelling, no swallowing or breathing issues.  He took 50mg of diphenhydramine.  Several hours later, pt. said still no breathing or swallowing issues, but now he has a sore on the roof of his mouth.
Chills, h.a., vomiting, fever 101.9, muscle aches. H.A. lasted 3 days-other sx.-lasted 3 days.
Information has been received from a physician concerning a 16 weeks old male who was vaccinated with the second 2ml dose of ROTATEQ vaccine. A week after receiving the second dose the patient experienced diarrhea and a green stool. The patient was sick for 3-4 days. At the time of this report, the patient was recovered. The patient sought unspecified medical attention. Additional information has been requested.
This case was reported by a other health professional via call center representative and described the occurrence of pain in a 60-year-old female patient who received Shingrix (batch number 3S354, expiry date 4th July 2020) for prophylaxis. On 3rd May 2018, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 3rd May 2018, less than a day after receiving Shingrix, the patient experienced pain, spaced out, erythropapular rash, rash hemorrhagic and insomnia. On 4th May 2018, the patient experienced injection site numbness and injected limb mobility decreased. In May 2018, the patient experienced injection site erythema and injection site warmth. On an unknown date, the outcome of the pain, injection site erythema, spaced out, erythropapular rash, rash hemorrhagic, injection site numbness, injection site warmth, insomnia and injected limb mobility decreased were recovered/resolved. It was unknown if the reporter considered the pain, injection site erythema, spaced out, erythropapular rash, rash hemorrhagic, injection site numbness, injection site warmth, insomnia and injected limb mobility decreased to be related to Shingrix. Additional details were provided as follows: The medical assistant stated that the patient had a reaction to the shot of the Shingrix. The patient mentioned at bedtime she was in pain and could not sleep, she did not mention where the pain exactly was. The patient also noticed tiny red bumps on her left foot which was sore and occasionally bleeding. The patient felt spaced out throughout the day of vaccination. Next morning (on 4th May 2018), the patient felt numbness in her arm at the injection site, and she could not lift her arm. On third day, after vaccination the patient's injection site was red and hot to touch. The patient stated it lasted for a few days and she recovered.
No adverse event. A slight local reaction that has resolved. Pt was not eligible for 3rd dose.
Numbness in legs and feet. Waist down numbness and tingling (no paralysis). Not complete numbness, surface numbness and a feeling of deadness in legs and feet. This lasted 5 days and was gone on the 6th day.
hives on  hands and ankles. The hives have gradually spread to all extremities (arms and legs); The hives have gradually spread to all extremities (arms and legs) and are red, hot, and itchy.; The hives have gradually spread to all extremities (arms and legs) and are red, hot, and itchy.; The hives have gradually spread to all extremities (arms and legs) and are red, hot, and itchy.; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 17:15 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 in Oct2020. The patient did not receive any concomitant medications. The patient had no known allergies to medications, food or other products.  Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 19:30, the patient experienced hives on hands and ankles and gradually spread to all extremities (arms and legs) and were red, hot and itchy. The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with Hydroxyzine Pam and Prednisone. The clinical outcome of the event hives, extremities hot feeling of, erythema of extremities and itchy was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.  Follow-up (20Ju2021):Amendment: This follow-up report is being submitted to amend previously reported information: Include in VAERS Block updated as Block 13 and ticked Block 10.
Patient was given the DTaP/IPV (Quadracel) instead of the Pentacel.  Provider/Patient made aware.  Patient has had no s/s of adverse effect at the time of this report.  Patient will be returning for the HIB to be given separately.
This spontaneous report, was received from a consumer, concerning his son, a currently 5 year old male patient. The patient's pertinent medical history was not provided. The patient's concurrent conditions included asthma, allergy to latex, peanuts, gluten, sugar, red dye and dairy. The patient did not have any concomitant medication to report. On 20-MAR-2014, the patient was vaccinated with M-M-R II as routine vaccination, lot #J000154 and expiration date 09-JAN-2015 (strength, dose, frequency, anatomical location and route of administration were not reported). On 14-AUG-2014 the patient was vaccinated VARIVAX as routine vaccination, lot #J013905 and expiration date 30-OCT-2015 (strength, dose, frequency, anatomical location and route of administration were not reported). On 22-MAR-2018, the patient was vaccinated with PROQUAD as routine vaccination, lot #N028443 and expiration date 09-APR-2019. (strength, dose, frequency, anatomical location and route of administration were not reported). On an unknown date, reported as "after the administration of all three vaccinations", the patient was diagnosed with attention deficit/hyperactivity disorder (ADHD), autism and oppositional defiant disorder. The reporter stated that the patient showed aggressive behavior. It was also informed that on four different unspecified dates, the patient had been hospitalized due to asthma attacks. At the time of reporting, the patient had not recovered from ADHD, autism, oppositional defiant disorder and asthma attacks. The patient did not received any treatment for the adverse events. The patient had been evaluated by several psychologists and was referred to 10 hours of occupational therapy a week. The causal relationship between the vaccination with M-M-R II, vaccinated VARIVAX, PROQUAD and the events was not provided by the reporter. Upon internal review, autism was determined to be a medically significant adverse event.
Developed swelling in leg either that night or next day.  Seen in office on 11/3, U/S confirmed DVT.
Patient received Pfizer vaccine at 0657 into the left deltoid.  Vaccinator notified on-site provider (this writer).  Patient was very slow to communicate and was slumped back in chair with a slight tremor noted to right hand.  I notified charge nurse to call 911 and returned to the vaccine station.   At this time, patient was slumped back in chair, non-responsive and agonal breathing.  Sternal rub was performed without any response.  Carotid pulse palpated.  Patient then received 0.3 mg Epinephrine injection via epipen into her left thigh.   Patient was then assisted from the chair to the floor by this writer and vaccinator.  Vital signs obtained: BP 122/78, HR 71, RR 22, T 97.4, O2 96%.  Patient was again sternal rubbed with very minimal response.  2 liters oxygen applied via NC.  Repeat Vitals: 110/70, HR 71, 93% on 2 liters via nasal cannula. .  EMS arrived and patient was coherent, talking, and alert/oriented x3.  Patient was helped to sit and was able to sit without difficulty.  Patient encouraged to be transported to ER for evaluation.  Patient ambulated to ambulance stretcher and was taken to ambulance for transfer.
Hair loss, severe fatigue, severe flushing of face, nose, hands, feet. Pain where skin was flushing on face. Pain scale 9/10. Dermatographia.
Increased Tinnitus in both ears; Injected arm was sore; Nausea; Tired; Headache; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (Increased Tinnitus in both ears), VACCINATION SITE PAIN (Injected arm was sore), NAUSEA (Nausea), FATIGUE (Tired) and HEADACHE (Headache) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     The patient's past medical history included Tinnitus in 2019 and COVID-19 in August 2020.    On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1. On 29-Mar-2021, the patient experienced TINNITUS (Increased Tinnitus in both ears), VACCINATION SITE PAIN (Injected arm was sore), NAUSEA (Nausea), FATIGUE (Tired) and HEADACHE (Headache). At the time of the report, TINNITUS (Increased Tinnitus in both ears), VACCINATION SITE PAIN (Injected arm was sore), NAUSEA (Nausea), FATIGUE (Tired) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Relevant concomitant products usage were not reported by the reporter. Treatment details not included.
onset of rash, hives @ approx 48hr;rash consistent w/erythema multiforme/serum sickness;
Dose in syringe may have been out 1 hours past the 6 hour time limit on opened Moderna vial
CM localized allergic rxn to (L) anterior thigh. (+) Redness, (+) swelling. TX: BENADRYL; ORAPRED; TYLENOL/MOTRIN PRN; Cool compress.
Groggy; Sore all over; Nauseous; Headache; Major fatigue; Chills; Could not sleep; Sweats; This spontaneous case was reported by a consumer and describes the occurrence of INSOMNIA (Could not sleep), HYPERHIDROSIS (Sweats), SOMNOLENCE (Groggy), MYALGIA (Sore all over) and NAUSEA (Nauseous) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) for an unknown indication.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, the patient experienced INSOMNIA (Could not sleep), HYPERHIDROSIS (Sweats), MYALGIA (Sore all over), NAUSEA (Nauseous), HEADACHE (Headache), FATIGUE (Major fatigue) and CHILLS (Chills). On 04-Feb-2021, the patient experienced SOMNOLENCE (Groggy). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) at a dose of 1 dosage form and PARACETAMOL (TYLENOL) at a dose of 1 dosage form. On 05-Feb-2021, INSOMNIA (Could not sleep), HYPERHIDROSIS (Sweats), SOMNOLENCE (Groggy), MYALGIA (Sore all over), NAUSEA (Nauseous), HEADACHE (Headache), FATIGUE (Major fatigue) and CHILLS (Chills) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Feb-2021, Heart rate: 95-105 (High) 95-105 bpm and 120-130 (High) 120-130. On 04-Feb-2021, Heart rate: 50-60 (normal) 50-60 beats per minute.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication includes BC Powder.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Follow-up information received on 29-jun-2021 contains event Groggy was updated.
Developed a rash at injection site on left arm 8 days after getting the injection.  Rash is mild but thought it unusual that the rash didn't appear until 8 days after getting the vaccine.
Pfizer-BioNTech COVID-19 Vaccine EUA  I did not experience any symptoms until the night following the vaccination.  Around 3:30am (01/14/2021), I was awoken by intense chills.  I was restless throughout the rest of the night, having hot and cold flashes.  I woke up around 8:20am and felt that I had a subjective fever.  I was also experiencing intense body ache and headache.  I took my temperature and it showed to be 100.6ºF.  I was still experiencing chills despite also feeling hot at the same time.  After an hour, my temperature was 101ºF.  I took 2 naproxen sodium tablets (440mg) to relieve fever.  Around 10:45am, my fever reduced but my body ache and headache stayed at the same pain level.  Around 2pm, I took 2 tablets of ibuprofen (400mg).  My headache stopped around 8:00pm.  My body aches stopped the morning of 01/15/2021.
Patient has a lump under the skin at the injection site.  This has led to some discomfort and unusual amount of pain that has him attempting to be seen by his primary provider.  He has been urged to seek attention from an urgent care facility, but his response was, "I don't want to be a wimp about this, I'll hold out until I can see my primary doctor." This started almost immediately after his second dose.  He received the first dose in the other arm 4 weeks prior without any reaction at all.
This is a 62-year-old female with past medical history of chronic respiratory failure, COPD, chronic back pain issues who was recently treated for bronchitis versus pneumonia by her primary care physician.  She states she continues to have her chronic cough which was somewhat worse than her baseline.  Her and her grandson got diagnosed with COVID-19 4/6/2021.  Patient was redirected to the emergency department, chest x-ray was unremarkable.  CT angiogram of the chest was negative for any pulmonary embolism, consistent with emphysema.  We started on IV Decadron, monitor inflammatory markers.  Repeat chest x-ray done in 48 hr remains negative for any acute infiltrates.
Patient completed their COVID-19 vaccine series on 3/23/21. Patient was admitted to the reporting hospital on 9/25/21 for COVID pneumonia. Symptoms included malaise, shortness of breath, and myalgias. Patient had onset of symptoms on 9/13, tested positive on 9/15. He was seen in clinic on 9/21 and started on dexamethasone 4mg daily. Patient continues to be hospitalized.
Severe dry coughing, throat felt like it was closing -which it was, flushed and body aches.  Almost had to use Epi Pen but, immediately took three regular Benadryl, which helped with swollen throat. Lasted app. one hour until the Benadryl started working. Dry cough remained.
Looked dazed, began shaking all over, eyes turned to back of head, became purple, after approx 3mins, started crying and became very sleepy. HX present illness: syncopal episode, evening of admission noted to walk across floor and began looking dazed and began shaking all over. Mother picked him and noted that his eyes were turning back in his head and he became "purple". Began crying after about 3 minutes of shaking and then became sleepy. Brought to ER. No HX of seizure but mother mentioned that child had one or two previous episodes of looking dazed and "turning purple" without the shaking. Week prior to this admission child was seen in this ER because his left foot turned in and he was limping. Child examined and no etiology was found at that time thought he was just trying to walk and that was the cause of his limping.  Admitted for observation. No seizure activity noted during hospitalization.  PE: Temp 99.5, WNL Tympanic membranes are normal tubes are inserted and both are dry. Impression: Possible Seizure DC DX: Syncopal episode, possible seizure activity.  .
Hospitalized 9/13/22-9/19/22 constipation, syncope, cough, respiratory failure, hypoxia, UTI,  PNA,
Immediate wheal and redness at vaccine site, no resp symp. Baby did fine and rash was gone by next day.
Patient called stating that he has a rash localized the the injection site on the right deltoid, that he believes to be shingles, caused by the injection. The patient states that he forgot to remove the bandaid on the site of injection for 3-5 days after receiving the vaccination. When he removed the bandage, he said that there were multiple small spots in the shape of a square under the bandage. He called 03/30 to notify us, 14 days after receipt of the vaccine, and about 10 days after removing bandage. Patient states spots on arms itch, but are not painful. States they are scabbed over. Denies any signs of bacterial infection at site of injection, or other systemic symptoms of infection. No other spots have appeared on body outside of the area of injection site.